BASIS OF PRESENTATION AND SIGNIFICANT ACCCOUNTING POLICIES - Narrative (Details) |
1 Months Ended | 3 Months Ended | 6 Months Ended | |||
|---|---|---|---|---|---|---|
|
Mar. 31, 2024
USD ($)
|
Jun. 30, 2025
USD ($)
|
Jun. 30, 2024
USD ($)
|
Jun. 30, 2025
USD ($)
clinicalTrial
|
Jun. 30, 2024
USD ($)
|
Dec. 31, 2024
USD ($)
|
|
| New Accounting Pronouncements or Change in Accounting Principle [Line Items] | ||||||
| Number of phase 3 clinical trials in process | clinicalTrial | 4 | |||||
| In-process research and development | $ 65,200,000 | $ 0 | $ 0 | $ 0 | $ 65,205,000 | |
| Equity method investments | 0 | 0 | ||||
| Restructuring expenses | $ 13,800,000 | |||||
| Equity Method Investments | ||||||
| New Accounting Pronouncements or Change in Accounting Principle [Line Items] | ||||||
| In-process research and development | 0 | $ 3,400,000 | 0 | $ 3,400,000 | ||
| FILSPARI | ||||||
| New Accounting Pronouncements or Change in Accounting Principle [Line Items] | ||||||
| Zero cost inventory | $ 1,500,000 | $ 1,500,000 | ||||
| X | ||||||||||
- Definition In Process Research And Development Expense No definition available.
|
| X | ||||||||||
- Definition Inventory Current And Non Current Net No definition available.
|
| X | ||||||||||
- Definition Number Of Phase Three Clinical Trials In Process No definition available.
|
| X | ||||||||||
- Definition This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of costs incurred to date for the specified restructuring cost. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|